EHA 2022 – Constantine Tam
Constantine Tam highlights the most relevant findings presented at EHA 2022 as well as promising modes of action of new agents in the treatment of indolent lymphomas. He explains how resistance to BTK inhibitors can be addressed in B-cell malignancies while giving an outlook on a BTK protein degrader and finally summarizes the long-term results obtained with zanubrutinib compared to ibrutinib in the ASPEN trial in patients with WM.
Here is the full EHA 2022 report.
More posts
Preface – EHA 2022
After 2 years of the COVID-19 pandemic, the Annual Meeting of the American Society of Clinical Oncology, held in Chicago, USA, and virtually from 3rd–7th June 2022, featured nearly 250 oral as well as over 2,200 poster presentations. Shortly thereafter, the 27th Congress of the European Hematology Association 2022, held in Vienna, Austria, and virtually, from 9th–12th June 2022, saw leading experts from around the world gather again to further discuss the most exciting updates in the field of hematology with key updates summarized in 200 oral presentations and 1,400 posters.
